Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2019 May 15;25(10):2956-2962. doi: 10.1158/1078-0432.CCR-18-3777. Epub 2019 Jan 17.
In 2013, two seminal studies identified gain-of-function mutations in the Calreticulin () gene in a subset of /-negative myeloproliferative neoplasm (MPN) patients. CALR is an endoplasmic reticulum (ER) chaperone protein that normally binds misfolded proteins in the ER and prevents their export to the Golgi and had never previously been reported mutated in cancer or to be associated with hematologic disorders. Further investigation determined that mutated is able to achieve oncogenic transformation primarily through constitutive activation of the MPL-JAK-STAT signaling axis. Here we review our current understanding of the role of mutations in MPN pathogenesis and how these insights can lead to innovative therapeutics approaches.
2013 年,两项开创性的研究在一部分 /-阴性骨髓增殖性肿瘤(MPN)患者中鉴定出钙网织蛋白(Calreticulin,CALR)基因的获得性功能突变。CALR 是内质网(Endoplasmic reticulum,ER)伴侣蛋白,通常在 ER 中结合错误折叠的蛋白质,防止它们输出到高尔基体,并且以前从未在癌症中报道过突变或与血液疾病相关。进一步的研究确定,突变的 CALR 主要通过 MPL-JAK-STAT 信号轴的组成性激活来实现致癌转化。在这里,我们回顾了我们对 CALR 突变在 MPN 发病机制中的作用的现有认识,以及这些见解如何为创新的治疗方法提供思路。